ProSciento, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProSciento, Inc. - overview
Established
2003
Location
Chula Vista, CA, US
Primary Industry
Healthcare IT
About
ProSciento, Inc. is a clinical research organization focused on metabolic diseases, providing expertise in drug and device development to enhance patient outcomes across global markets. ProSciento, Inc. , founded in 2003, is headquartered in Chula Vista, US.
The company specializes in clinical research services for metabolic diseases, including obesity and diabetes. Marcus Hompesch serves as CEO, steering the organization towards innovative research solutions. ProSciento has made significant strides, including a recent investment deal in September 2020, which underscores its position in the market. ProSciento specializes in clinical research services dedicated to metabolic diseases, particularly obesity, diabetes, and MASLD/MASH.
Their offerings include comprehensive support for drug and device development, leveraging a team of experts to enhance patient outcomes. The company serves pharmaceutical and biotech clients engaged in metabolic disease research across North America, Europe, and Asia-Pacific. ProSciento generates revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, engaging in B2B transactions to provide tailored clinical research services. Revenue is derived from project-based contracts for specific research services associated with drug and device trials, involving milestone payments as research phases are completed.
ProSciento aims to utilize the recent investment from 1315 Capital, secured in September 2020, to enhance its service offerings and expand into new markets. The company plans to launch new products focusing on innovative therapeutic solutions for metabolic diseases and is targeting growth in regions such as Europe and Asia-Pacific by the end of 2023.
Current Investors
1315 Capital
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT
Website
www.prosciento.com
Verticals
HealthTech
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
ProSciento, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | ProSciento, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.